Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings, Inc. reports developments tied to its clinical-stage biotherapeutics platform for oral delivery of biologics and drugs. The company’s RaniPill® capsule technology is designed to deliver drug substances such as antibodies, proteins, peptides and oligonucleotides as an alternative to subcutaneous injection or intravenous infusion.
Recurring RANI news includes clinical and preclinical updates for RaniPill-based programs, including RT-114, a GLP-1/GLP-2 dual agonist program for obesity, and oral semaglutide work. Company updates also cover financial results, collaboration and license activity, private placement financing, manufacturing and supply-chain capabilities, pipeline prioritization, investor conference participation, and leadership or advisory appointments supporting platform and clinical strategy.
Rani Therapeutics announced preliminary FDA feedback on RT-102, suggesting a 505(b)(2) development pathway could be suitable. The company presented updates on its clinical trials, including positive topline results from the Phase 1 study, achieving all endpoints and demonstrating good tolerability. The anticipated key milestones for 2023 include the initiation of the Phase 2 trial for RT-102 in osteoporosis and three additional Phase 1 studies. Rani's preliminary cash position stands at approximately $99 million as of December 31, 2022.
Rani Therapeutics announced positive topline results from Part 2 of its Phase 1 study for RT-102, an oral drug for osteoporosis. The study met all endpoints, with a 91% success rate in drug delivery via the RaniPill™ GO capsule, which was well tolerated by the participants, showing no serious adverse events. The data supports moving to a Phase 2 trial anticipated in H2 2023. Approximately 185 capsules have been administered in clinical studies, reinforcing the viability of the RaniPill™ platform for oral biologic delivery.
Rani Therapeutics reported its Q3 2022 financial results and key corporate updates on Nov. 10, 2022. The highlights include positive topline results from the Phase 1 study of RT-102, a proprietary PTH formulation, and the initiation of preclinical development for RT-111, a biosimilar targeting autoimmune conditions. Financially, Rani ended Q3 with cash reserves of $98.7 million. Although R&D expenses decreased to $9.1 million, the net loss reduced to $16.2 million from $28.7 million year-over-year. Upcoming milestones involve additional data from RT-102 and new Phase 1 studies in 2023.
Rani Therapeutics, a clinical stage biotherapeutics company, will present at the Stifel Healthcare Conference on November 15-16, 2022. CEO Talat Imran is scheduled to speak on November 16 at 9:45 AM EST. The company focuses on oral delivery of biologics through its innovative RaniPill capsule technology, aimed at replacing injections with oral dosing. Interested parties can access live webcasts from the Investor Relations section of their website, with replays available for 90 days post-presentation.
Rani Therapeutics announced the preclinical development of RT-111, an oral ustekinumab biosimilar targeting psoriatic arthritis, ulcerative colitis, Crohn's disease, and psoriasis. The product aims to simplify patient treatment by replacing injections with oral delivery.
Additionally, topline data for RT-102 is expected in Q4 2022, alongside the start of in vivo studies for the RaniPill HC. The company also plans to ramp up its pipeline with three new Phase 1 studies in 2023.
Rani Therapeutics Holdings (Nasdaq: RANI) announced its participation in the H.C. Wainwright Global Investment Conference, scheduled for September 12-14, 2022. CEO Talat Imran will deliver a presentation on September 12 at 8:30 AM EST. The conference will be accessible virtually and in-person, with a webcast available via the Investor Relations section of Rani's website. Rani Therapeutics focuses on innovative oral delivery systems for biologics, utilizing its patented RaniPill capsules to replace traditional injection methods.
Rani Therapeutics announced the termination of its previously announced underwritten public offering of Class A common stock, as management assessed the current market conditions as unfavorable. Consequently, no shares will be sold in this offering. The company asserted it has adequate capital to fund operations into mid-2024. The offering was to be conducted under an effective shelf registration statement. Forward-looking statements regarding cash reserves highlight potential risks and uncertainties affecting future results.
Rani Therapeutics Holdings has announced its intention to conduct an underwritten public offering of Class A common stock. The offering may include a 30-day option for underwriters to purchase up to 15% more shares. This action is contingent on market conditions and could affect the stock's performance. BofA Securities, Cantor, and UBS Investment Bank are leading the offering, which is being facilitated under a shelf registration statement effective as of August 10, 2022. The company emphasizes that no securities will be sold in jurisdictions where the offering would be unlawful.
Rani Therapeutics announced positive topline results from its Phase 1 trial of RT-102, a treatment for osteoporosis, demonstrating high oral bioavailability and successful drug delivery. The company completed a debt financing agreement of up to $45 million, ensuring operations are funded into mid-2024. Rani plans to initiate a third Phase 1 clinical trial and expects topline results from the repeat-dose portion of RT-102 by Q4 2022. As of June 30, 2022, cash and equivalents were $97.2 million, while R&D expenses rose significantly year-over-year to $9.5 million.
Rani Therapeutics announced positive topline results from its Phase 1 clinical study of RT-102, an oral capsule with human parathyroid hormone (PTH) analog for osteoporosis treatment. The study demonstrated that RT-102 was well-tolerated, with a 95% drug delivery success rate and a bioavailability of 300-400% greater than subcutaneous injections. The company aims to file an IND for Phase 2 trials by Q3 2023, building on the success of RT-101 and further validating the RaniPill platform.